CD8A and glioblastoma: DC vaccines that were transfected with personalized tumor-associated antigen mRNA triggered specific CD4+ and CD8+ T cell responses in patients with advanced lung cancer or glioblastoma multiforme (GBM), and these responses were associated with favorable overall survival without significant autoimmune side effects (115).